NSRG-23. 5-AMINOLEVULINIC ACID GUIDED RESECTION OF PAEDIATRIC CENTRAL NERVOUS SYSTEM TUMOURS: THE LARGEST SINGLE CENTRE SERIES IN THE UK

Abstract BACKGROUND 5-aminolevulinic acid (5-ALA, Gliolan) is widely used in adults for facilitating the resection of high-grade gliomas. However, its safety and efficacy in the paediatric population remains to be established. We present the UK’s first case series of 10 patients, undergoing 11 opera...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2018-06, Vol.20 (suppl_2), p.i150-i150
Main Authors: Burford, Charlotte, Kalyal, Nida, Pandit, Anand, Lavrador, Jose Pedro, Bleil, Cristina, Kailaya-Vasan, Ahilan, Zebian, Bassel
Format: Article
Language:English
Subjects:
Abstracts
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract BACKGROUND 5-aminolevulinic acid (5-ALA, Gliolan) is widely used in adults for facilitating the resection of high-grade gliomas. However, its safety and efficacy in the paediatric population remains to be established. We present the UK’s first case series of 10 patients, undergoing 11 operations with 5-ALA. METHODS 10 consecutive patients (aged 1.6-15 years) underwent pre-operative administration of 20mg/kg of 5-ALA. The tumours were visualised intra-operatively under violet-blue light and the presence and usefulness of fluorescence was assessed. RESULTS Strong fluorescence was observed in two WHO grade III ependymomas and a GBM (IV). Moderate fluorescence was seen in one pilocytic astrocytoma (I) and a pilomxyoid astrocytoma (II). Weak fluorescence was observed in a diffuse astrocytoma (II). The tumours types which showed no fluorescence included: a pilocytic astrocytoma, a glioneuronal tumour (II) and an anaplastic medulloblastoma (IV). No significant adverse drug reactions were recorded in any of the patients. CONCLUSIONS Our case series adds to the evidence base supporting the safety of 5-ALA in the paediatric population. However, the diverse range of responses to 5-ALA in these tumours highlights the need for further trials into its usefulness in specific tumour types.
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/noy059.545